First Tracks Biotherapeutics is trading at $33.97, down 5.19%, with no confirmed direct catalyst identified for September 25, 2026. - Recent investor-conference news and analyst coverage remain earlier catalysts. - Broader markets are higher, but elevated Treasury yields continue pressuring growth-sensitive biotech valuations. - The decline diverges from major indexes; monitor for delayed news.